VEVIX | VMVIX | VEVIX / VMVIX | |
Total Expense Ratio | 0.58 | 0.19 | 305% |
Annual Report Gross Expense Ratio | 0.58 | 0.19 | 305% |
Fund Existence | 15 years | 19 years | - |
Gain YTD | 1.694 | 5.177 | 33% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 2000000 | 3000 | 66,667% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 17.3B | 31B | 56% |
Annual Yield % from dividends | 1.15 | 2.10 | 55% |
Returns for 1 year | -6.66 | 7.67 | -87% |
Returns for 3 years | -2.06 | 17.46 | -12% |
Returns for 5 years | 35.85 | 65.08 | 55% |
Returns for 10 years | 46.40 | 87.80 | 53% |
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
PPH | 87.35 | 1.20 | +1.39% |
VanEck Pharmaceutical ETF | |||
SPYI | 51.75 | -0.06 | -0.12% |
NEOS S&P 500(R) High Income ETF | |||
IBTP | 25.56 | -0.06 | -0.23% |
iShares iBonds Dec 2034 Term Trsy ETF | |||
GYLD | 13.36 | -0.03 | -0.26% |
Arrow Dow Jones Global Yield ETF | |||
GSC | 51.99 | -0.39 | -0.75% |
Goldman Sachs Small Cap Equity ETF |